

RUTGERS CANCER INSTITUTE LUNG TUMOR BOARD

Provided by Rutgers Cancer Institute
Department of Radiology and Pathology

Interesting Cases of the Week
Rutgers Cancer Institute via Webex
Thursday, August 21, 2025 8:00-9:00AM

Missak Haigentz, MD, Salma Jabbour, MD, Ioannis Kontopidis, MD, John Langenfeld, MD, Kevin Law, MD, Benjamin Medina, MD, Malini Patel, MD, Judith Amorosa, MD, Imraan Jan, DO, Arunabh Sekhri, MD, Allan Louis Cruz, MD, Sivraj Muralikrishnan, MD, KarLeung Siu, MD

Learning Objectives

At the conclusion of this activity, participants should be better able to:

- Discuss clinical trials specific eligibility criteria and treatment protocols
- Improve the care of the cancer patients through the exchange of information among participating clinicians
- Promote research on oncology that will continually improve the quality of care for cancer patients

Target Audience

This activity is designed for medical oncologists, surgical oncologists, general surgeons, radiation oncologists, radiologists, pulmonologists, pathologists, physician's assistants, pharmacists, nurses and nurse practitioners.

Accreditation



In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians: Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is awarded 1 ANCC contact hour

Pharmacists: This knowledge-based activity qualifies for 1 contact hour of continuing pharmacy education credit.

Disclosure Declarations

The following speakers have relevant financial relationships with ineligible companies: Dr. Haigentz: Member Advisory Board: AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Janssen Pharmaceuticals. Dr. Jabbour: Consultant: AstraZeneca, Merck, Radiologica; Grant/Research Support: Beigene, Merck.

Drs. Amorosa, Kontopidis, Langenfeld, Law, Medina, Patel, Jan, Sekhri, Cruz, Muralikrishnan and Siu have no relevant financial relationships with ineligible companies to disclose.

Speakers are required to disclose discussion of off-label/investigational uses of commercial products/devices in their presentation. These disclosures will be made to the audience at the time of the activity.

Planning Committee: Dr. Missak Haigentz (Activity Director/Content Reviewer) has the following relevant financial relationships with ineligible companies: Member, Advisory Board: AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Janssen Pharmaceuticals. Dr. John Langenfeld, Maryjoy Marzan, APRN, Michael Kane, RPh, BCOP, and Dr. Ioannis Kontopidis (Activity Director) have no relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed have been mitigated.

Rutgers Health CE Staff: Patrick Dwyer and Elizabeth Ward have no relevant financial relationships with ineligible companies to disclose.